Improved Survival Seen for Some with Pancreatic Cancer.
In two pancreatic cancer trials-the randomized phase III PRODIGE 24/CCTG PA.6 and PREOPANC-1 trials-researchers found that experimental drug regimens for patients with resectable adenocarcinomas increased overall survival or showed a trend in that direction. The findings could prompt changes in clinical practice for these patients.